Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs ... beyond small molecule drugs. Vertex's continued ...

WASHINGTON (AP) — Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction ...

While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs and potential ... new avenues for growth beyond small ...

The Foundation is challenging potential collaborators to submit proposals that will accelerate the pace of progress in CF drug discovery and development ... the CF Foundation continues to build a ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning ... Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for ...